Takeda Pharmaceutical Company Limited Adjustments For Finance Income Cost
Takeda Pharmaceutical Company Limited (TKPHF) reported Adjustments For Finance Income Cost of -JPY 163.52 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForFinanceIncomeCost · last filed 2025-06-25
| Period end | Adjustments For Finance Income Cost 12 month |
|---|---|
| 2025-03-31 | -163.52B JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | -167.76B JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | -106.78B JPY 20-F · filed 2025-06-25 |
| 2022-03-31 | -142.91B JPY 20-F · filed 2024-06-26 |
| 2021-03-31 | -143.11B JPY 20-F · filed 2023-06-28 |
| 2020-03-31 | -137.18B JPY 20-F · filed 2022-06-29 |
| 2019-03-31 | -66.45B JPY 20-F · filed 2021-06-29 |
| 2018-03-31 | 7.62B JPY 20-F · filed 2020-06-24 |